Immunogenicity and Safety of GlaxoSmithKline Biologicals’ Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 – 25 Years of Age

Overview

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current phase 3b study is designed to assess the immunogenicity and safety of GlaxoSmithKline Biologicals' HPV vaccine GSK580299 administered according to an alternative dosing schedule as compared to the standard dosing schedule in young female subjects aged 15 – 25 years. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Full Title of Study: “Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ HPV Vaccine GSK580299 Administered According to an Alternative Dosing Schedule as Compared to the Standard Dosing Schedule in Young Female Subjects Aged 15-25 Years”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 26, 2009

Interventions

  • Biological: Cervarix TM
    • Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
  • Biological: Cervarix TM
    • Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.

Arms, Groups and Cohorts

  • Experimental: Cervarix-12 Group
    • Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
  • Active Comparator: Cervarix-6 Group
    • Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies
    • Time Frame: One month after the third vaccine dose
    • Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination. Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.
  • Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies
    • Time Frame: One month after the third vaccine dose
    • Titer given as geometric mean titer (GMT).

Secondary Measures

  • Number of Subjects Seroconverted for Anti-HPV-16 and Anti-HPV-18 Antibodies
    • Time Frame: One month after the second vaccine dose
    • Seroconversion is defined as the appearance of anti-HPV-16 and/or anti- HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the sera of subjects seronegative before vaccination. Cut-off values were 8 enzyme-linked immunosorbent assay units per milliliter (EL.U/mL) for anti-HPV-16 antibodies and 7 EL.U/mL for anti- HPV-18 antibodies.
  • Titer of Anti-HPV-16 and Anti-HPV-18 Antibodies
    • Time Frame: One month after the second vaccine dose
    • Titer given as GMT.
  • Number of Subjects Reporting Solicited Local Symptoms
    • Time Frame: During the 7-day (Days 0-6) period following each vaccination
    • Solicited local symptoms assessed include pain, redness and swelling at the injection site.
  • Number of Subjects Reporting Solicited General Symptoms
    • Time Frame: During the 7-day (Days 0-6) period following each vaccination
    • Solicited general symptoms assessed include arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash, and urticaria.
  • Number of Subjects Reporting Unsolicited Adverse Events (AE)
    • Time Frame: During the 30-day (Days 0-29) period following each vaccination
    • An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
  • Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs), New Onset Autoimmune Diseases (NOADs), Serious Adverse Events (SAEs), and Medically Significant Conditions (MSCs)
    • Time Frame: During the entire study period (up to Month 18 or up to Month 12)
    • Entire study period = up to Month 18 Cervarix-12 & Month 12 Cervarix-6. NOCDs assessed include eg. autoimmune disorders (NOADs), asthma, type I diabetes. MSCs assessed include AEs prompting emergency room visits and physician office visits not related to common illnesses. An SAE is any untoward medical occurrence that: results in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.
  • Number of Subjects With Pregnancies and Their Outcomes
    • Time Frame: During the entire study period (up to Month 18 or Month 12)
    • Entire study period = up to Month 18 Cervarix-12 & Month 12 Cervarix-6 Number of pregnancies and pregnancy outcomes.
  • Number of Subjects Completing the 3-dose Vaccination Schedule
    • Time Frame: After the third vaccine dose

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects who the investigator believes that they and/or their parent(s)/Legally acceptable representative(s) (LAR) can and will comply with the requirements of the protocol – A female between and including 15 and 25 years of age at the time of the first vaccination. – Written informed consent obtained from the subject prior to enrolment. For subjects below the legal age of consent, written informed consent must be obtained from the subject's parents/legally acceptable representative (LAR), and written informed assent must be obtained from the subject. – Healthy subjects as established by medical history and/or clinical examination before entering into the study. – Subject must be of non-childbearing potential, or if she is of child bearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative urine pregnancy test and continue such precautions for 2 months after completion of the vaccination series. – Subject who had no more than 6 lifetime sexual partners prior to enrolment. Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. – Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. – Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before and 30 days after the first dose of vaccine. Planned administration/administration of routine vaccines up to 8 days before the first dose of study vaccine is allowed. Enrolment will be deferred until the patient is outside of specified window. – Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). – Previous vaccination against HPV or planned administration of any HPV vaccine other than that foreseen by the study protocol during the study period. – previous administration of components of the investigational vaccine – Cancer or autoimmune disease under treatment. – Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. – History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. – Hypersensitivity to latex – Acute disease at the time of enrolment. – Administration of immunoglobulins and/or any blood products within the three months preceding blood sampling. – Pregnant or breastfeeding female. – Female planning to become pregnant, likely to become pregnant (as determined by the investigator) or planning to discontinue contraceptive precautions during the study period starting at visit one and up to two months after the last vaccine dose. – Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal function abnormality as determined by physical examination or lab tests.

Gender Eligibility: Female

Minimum Age: 15 Years

Maximum Age: 25 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.